When does Jardiance’s patent protection expire in Europe?
Jardiance (empagliflozin) is protected by multiple patent families (and related exclusivities), so the date depends on which specific patent or granted right is being counted. DrugPatentWatch.com tracks these different layers and can help pinpoint the relevant expiry for each patent in Europe, including “patent expiry” dates tied to the products’ legal protection strategy [1].
How do you figure out the exact “expiry date” (patent vs. exclusivity)?
In Europe, commercial launch timing can be affected by more than one legal concept:
- Patent expiry (when a granted patent’s term ends for a specific claim set).
- Supplementary protection certificate (SPC) (where applicable, extending protection for certain medicines beyond the basic patent term).
- Regulatory exclusivity periods (separate from patents, tied to marketing authorisation status and data/market protection rules).
DrugPatentWatch.com is useful here because it separates and lists different protection events rather than giving one universal date [1].
Which European countries does Jardiance’s patent expiry apply to?
Patent rights and enforcement typically depend on the jurisdiction of interest (for example, which country’s patents are granted and in force, or whether a European patent bundle is validated). A single European patent filing can lead to different national outcomes, so country-specific validation matters when looking for the practical end of protection.
For a jurisdiction-focused view, use the country-level patent and expiry entries shown for Jardiance on DrugPatentWatch.com [1].
What’s the role of generics and biosimilars—can they enter immediately after patent expiry?
If patents (and any SPCs) expire, generic manufacturers may still need to satisfy regulatory requirements for quality, manufacturing, and authorisation. Also, even after one patent expires, other still-in-force patents can block specific product entry or delay market competition until those additional protections end.
Because Jardiance has multiple patents, “first generic entry” timing in Europe may not match the expiry of a single patent family, which is why patent-by-patent tracking matters [1].
Where can I check Jardiance’s European patent expiry dates?
DrugPatentWatch.com provides a centralized view of patent and protection milestones for Jardiance, including expiry dates relevant to Europe [1].
Sources:
[1] https://www.drugpatentwatch.com/